Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these findings may inform clinical decision-making in the second-line setting, following endocrine therapy plus CDK4/6 inhibitor therapy, for patients with ESR1-mutated tumors.
More Videos in Metastatic Breast Cancer Content Hub
This webinar, focused on challenging cases in metastatic breast cancer, was moderated by Ashkan Lashkari, MD, oncologist at Wellness Oncology, California, and included expert panelists Rebecca A. Shatsky,…
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, discusses optimization of therapy for patients with HER2-positive metastatic breast cancer. Dr Authal shares her experience with toxicity…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
Barbara Pistilli, MD, chair of the breast cancer unit, Gustave Roussy, Villejuif, France, provides a case-based discussion of therapeutic options for a patient with pretreated HR+/HER2- (IHC 0)…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University,…
